Vascular Biogenics Ltd.
VBLT
Price:
$0.156
Market Cap:
$12.11M
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal c...[Read more]
Industry
Biotechnology
IPO Date
2014-10-01
Stock Exchange
NASDAQ
Ticker
VBLT
The ROE as of September 2024 (TTM) for Vascular Biogenics Ltd. (VBLT) is -57.94%
According to Vascular Biogenics Ltd.’s latest financial reports and current stock price. The company's current ROE is -57.94%. This represents a change of 347.33% compared to the average of -12.95% of the last 4 quarters.
Vascular Biogenics Ltd. (VBLT) Historical ROE (quarterly & annually)
How has VBLT ROE performed in the past?
The mean historical ROE of Vascular Biogenics Ltd. over the last ten years is -44.53%. The current -57.94% ROE has changed 30.12% with respect to the historical average. Over the past ten years (40 quarters), VBLT's ROE was at its highest in in the December 2013 quarter at 22.93%. The ROE was at its lowest in in the September 2014 quarter at -115.78%.
Average
-44.53%
Median
-46.06%
Minimum
-143.51%
Maximum
73.65%
Vascular Biogenics Ltd. (VBLT) ROE by Quarter and Year
Discovering the peaks and valleys of Vascular Biogenics Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 160.83%
Maximum Annual ROE = 73.65%
Minimum Annual Increase = -176.35%
Minimum Annual ROE = -143.51%
| Year | ROE | Change |
|---|---|---|
| 2022 | -143.51% | 160.83% |
| 2021 | -55.02% | -30.08% |
| 2020 | -78.69% | 42.66% |
| 2019 | -55.16% | 43.16% |
| 2018 | -38.53% | 112.46% |
| 2017 | -18.14% | -51.95% |
| 2016 | -37.74% | -11.26% |
| 2015 | -42.53% | -14.24% |
| 2014 | -49.59% | -167.33% |
| 2013 | 73.65% | -176.35% |
Vascular Biogenics Ltd. (VBLT) Average ROE
How has VBLT ROE performed in the past?
The current ROE of Vascular Biogenics Ltd. (VBLT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-92.41%
5-year avg
-74.18%
10-year avg
-44.53%
Vascular Biogenics Ltd. (VBLT) ROE vs. Peers
How is VBLT’s ROE compared to its peers?
Vascular Biogenics Ltd.’s ROE is greater than Revelation Biosciences, Inc. (-243.91%), greater than Zura Bio Limited (-35.45%), greater than Phio Pharmaceuticals Corp. (-142.68%), greater than ZyVersa Therapeutics, Inc. (-172.51%), greater than TransCode Therapeutics, Inc. (-597.47%), less than Panbela Therapeutics, Inc. (0%), less than Virax Biolabs Group Limited (545.45%), greater than Allarity Therapeutics, Inc. (-115.10%), greater than ContraFect Corporation (-704.78%), less than Avenue Therapeutics, Inc. (403.13%), greater than Acumen Pharmaceuticals, Inc. (-749.10%), greater than HOOKIPA Pharma Inc. (-24.63%), greater than Day One Biopharmaceuticals, Inc. (-51.77%), greater than Inozyme Pharma, Inc. (-122.70%), greater than Terns Pharmaceuticals, Inc. (-68.93%), greater than X4 Pharmaceuticals, Inc. (-39.58%), less than Galera Therapeutics, Inc. (32.93%), less than null (21.95%),
| Company | ROE | Market cap |
|---|---|---|
| -243.91% | $1.43M | |
| -35.45% | $230.86M | |
| -142.68% | $2.25M | |
| -172.51% | $2.70M | |
| -597.47% | $4.56M | |
| 0% | $1.75M | |
| 545.45% | $15.24M | |
| -115.10% | $7.01M | |
| -704.78% | $1.72M | |
| 403.13% | $4.05M | |
| -749.10% | $133.38M | |
| -24.63% | $159.50M | |
| -51.77% | $1.25B | |
| -122.70% | $312.42M | |
| -68.93% | $549.60M | |
| -39.58% | $109.78M | |
| 32.93% | $4.08M | |
| 21.95% | $0 |
Build a custom stock screener for Vascular Biogenics Ltd. (VBLT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vascular Biogenics Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Vascular Biogenics Ltd. (VBLT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Vascular Biogenics Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Vascular Biogenics Ltd.'s ROE?
How is the ROE calculated for Vascular Biogenics Ltd. (VBLT)?
What is the highest ROE for Vascular Biogenics Ltd. (VBLT)?
What is the 3-year average ROE for Vascular Biogenics Ltd. (VBLT)?
What is the 5-year average ROE for Vascular Biogenics Ltd. (VBLT)?
How does the current ROE for Vascular Biogenics Ltd. (VBLT) compare to its historical average?